Skip to main
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insmed is a biopharmaceutical company with a positive outlook, driven by the strong commercial performance of its two respiratory products, Arikayce and Brinsupri. The company has a diverse and promising pipeline focused on respiratory, immunology, and rare neurological diseases, supported by various technologies and modalities. With its strong financial position and expectations for significant revenue growth from its lead programs, Insmed is a top pick for investors.

Bears say

Insmed is facing significant downside risks to its price target and rating due to clinical and commercial risks associated with its products, including Arikayce and TPIP. Additionally, strong competition from other companies in the same therapeutic areas may hinder Insmed's commercial success, especially for its TPIP product which faces competition from Tyvaso and Yutrepia. Changes to Insmed's financial model, including increased expenses and delays in product launches, also contribute to our negative outlook on the stock.

Insmed (INSM) has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 20 analysts, Insmed (INSM) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $209.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $209.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.